WallStSmart

Edwards Lifesciences Corp (EW)vsENvue Medical Inc. (FEED)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Edwards Lifesciences Corp generates 298492% more annual revenue ($6.51B vs $2.18M). EW leads profitability with a 15.4% profit margin vs 0.0%. EW earns a higher WallStSmart Score of 51/100 (C-).

EW

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 8.0Value: 5.3Quality: 8.5
Piotroski: 3/9Altman Z: 4.48

FEED

Avoid

30

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 5.0Quality: 4.5
Piotroski: 2/9Altman Z: -1.85
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EWUndervalued (+69.1%)

Margin of Safety

+69.1%

Fair Value

$256.77

Current Price

$91.60

$165.17 discount

UndervaluedFair: $256.77Overvalued

Intrinsic value data unavailable for FEED.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EW4 strengths · Avg: 9.3/10
Debt/EquityHealth
0.0710/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.4810/10

Safe zone — low bankruptcy risk

Market CapQuality
$52.80B9/10

Large-cap with strong market position

Operating MarginProfitability
29.8%8/10

Strong operational efficiency at 29.8%

FEED2 strengths · Avg: 10.0/10
Price/BookValuation
0.1x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0410/10

Conservative balance sheet, low leverage

Areas to Watch

EW4 concerns · Avg: 2.8/10
PEG RatioValuation
2.224/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

P/E RatioValuation
54.5x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-25.4%2/10

Earnings declined 25.4%

FEED4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$3.72M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : EW

The strongest argument for EW centers on Debt/Equity, Altman Z-Score, Market Cap. Profitability is solid with margins at 15.4% and operating margin at 29.8%. Revenue growth of 13.6% demonstrates continued momentum.

Bull Case : FEED

The strongest argument for FEED centers on Price/Book, Debt/Equity.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 54.5x leaves little room for execution misses.

Bear Case : FEED

The primary concerns for FEED are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

EW profiles as a mature stock while FEED is a value play — different risk/reward profiles.

FEED carries more volatility with a beta of 1.35 — expect wider price swings.

EW is growing revenue faster at 13.6% — sustainability is the question.

EW generates stronger free cash flow (585M), providing more financial flexibility.

Bottom Line

EW scores higher overall (51/100 vs 30/100), backed by strong 15.4% margins and 13.6% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

ENvue Medical Inc.

HEALTHCARE · MEDICAL DEVICES · USA

ENvue Medical Inc. (FEED) is a pioneering healthcare technology company that specializes in the development of cutting-edge medical devices and integrated software solutions aimed at enhancing patient care management. By leveraging innovation to optimize health outcomes and streamline recovery processes, ENvue is well-positioned to capitalize on substantial growth opportunities within the dynamic healthcare landscape. With a strong product pipeline and strategic collaborations, the company represents a compelling investment for institutional investors interested in the future of medical devices and digital health advancements.

Want to dig deeper into these stocks?